adapalene vs ustekinumab
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of adapalene and ustekinumab. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Differin
Stelara
No summary available.
Ustekinumab-aekn (Stelara) is a medicine that helps control inflammation in your body. It works by blocking certain proteins that cause inflammation.
Information not available.
This medicine can treat moderate to severe plaque psoriasis in adults and children 6 years and older. It can also treat active psoriatic arthritis in adults and children 6 years and older. In adults, it can treat moderately to severely active Crohn’s disease and ulcerative colitis.
Information not available.
Ustekinumab-aekn blocks two proteins in your body called interleukin-12 and interleukin-23. These proteins cause inflammation. By blocking them, the medicine helps reduce inflammation and the symptoms of your condition.
- • Dry skin
- • Contact dermatitis (skin rash)
- • Burning feeling on the skin where you put the medicine
- • Skin irritation
- • Common cold symptoms (nasopharyngitis)
- • Upper respiratory infection
- • Headache
- • Tiredness (fatigue)
- • Vomiting (for Crohn's disease induction)
- Dry Skin 44,990
- Skin Burning Sensation 41,633
- Acne 39,264
- Erythema 38,379
- Skin Irritation 26,225
- Fatigue 6,589
- Psoriasis 6,433
- Pain 6,033
- Arthralgia 5,628
- Crohn^S Disease 5,563
No specific warnings noted.
Ustekinumab-aekn can increase your risk of getting serious infections. Tell your doctor if you have any signs of an infection, like fever, cough, or body aches. Before starting this medicine, your doctor should check you for tuberculosis (TB). This medicine may also increase your risk of certain cancers. Contact your doctor right away if you have a severe allergic reaction. This medicine can also cause a rare condition called Posterior Reversible Encephalopathy Syndrome (PRES).
No pregnancy information available.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if ustekinumab-aekn will harm your unborn baby. Talk to your doctor about the risks and benefits of using this medicine during pregnancy. It is also not known if ustekinumab-aekn passes into breast milk.
Also Compare, Nearby Drugs
Compare adapalene with
How to Read This adapalene vs ustekinumab Comparison
adapalene is classified in the Retinoid (Topical) drug class, while ustekinumab sits within the Anti-IL-12/23 Monoclonal Antibody class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are split between OTC and prescription status, which affects access and supervision.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, adapalene has 190,491 submissions while ustekinumab has 30,246. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for adapalene or ustekinumab.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.